© 2005-2012 American Society of Clinical Oncology (ASCO). All rights reserved worldwide.
- Bisphosphonates are an important treatment option that can help to strengthen bones in people with multiple myeloma.
- The two bisphosphonates used in the United States are pamidronate and zoledronic acid; talk with your doctor about the benefits and risks of each drug.
- Patients should receive bisphosphonate treatment every three to four weeks for no longer than two years because of the potential side effects.
- Before receiving bisphosphonate treatment, patients should schedule an examination with a dentist.
To help doctors give their patients the best possible care, the American Society of Clinical Oncology (ASCO) asks its medical experts to develop recommendations for specific areas of cancer care. In 2002, ASCO published a clinical practice guideline about bisphosphonate treatment for multiple myeloma. The scope of this guideline was expanded and updated in 2007. This guide for patients is based on ASCO's recommendations.
As you read this guide, please keep in mind that every person treated for cancer is different. These recommendations are not meant to replace your judgment or that of your doctor. The final decisions you and your doctors make will be based on your individual circumstances.